Robert C. Flanigan
  • Albert J. and Claire R. Speh Professor of Urology
  • Department Chairperson, Urology
  • Urology
Bladder Cancer, Kidney Cancer, Testicular Cancer, Kidney Transplant, Prostate Cancer
Board Certifications
  • Urology - General Cert: AM Board of Urology

New Onset Postoperative Atrial Fibrillation Predicts Long-Term Cardiovascular Events Following Radical CystectomyBlackwell,R. H.; Ellimoottil,C.; Bajic,P.; Kothari,A.; Zapf,M.; Kliethermes,S.; Flanigan,R. C.; Quek,M. L.; Kuo,P. C.; Gupta,G. N.The Journal of urology 2015 ; ( ):

A primer on clinical trial designEllimoottil,C.; Vijan,S.; Flanigan,R. C.Urologic oncology 2015 ; ( ):

New Modalities for the Evaluation and Surveillance of Complex Renal CystsEllimoottil,C.; Greco,K. A.; Hart,S.; Patel,T.; Sheikh,M. M.; Turk,T. M.; Flanigan,R. C.The Journal of urology 2014 ; ( ):

Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinomaWang,L.; Mudaliar,K.; Mehta,V.; Barkan,G. A.; Quek,M. L.; Flanigan,R. C.; Picken,M. M.Virchows Archiv : an international journal of pathology 2014 ; ( ):

Acute acalculous cholecystitis after radical cystectomy: a report of two casesGreco,K. A.; Flanigan,R. C.; Quek,M. L.International journal of urology : official journal of the Japanese Urological Association 2013 ;20(4):453-454

How to prepare and present scientific manuscripts in EnglishHannick,J. H.; Flanigan,R. C.International journal of urology : official journal of the Japanese Urological Association 2013 ;20(2):136-139

Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancerRao,M. V.; Ellimoottil,C.; Sondej,T.; Flanigan,R. C.; Quek,M. L.Urologic oncology 2013 ;31(6):857-861

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate RadiotherapyRao,M. V.; Quek,M. L.; Jayram,G.; Ellimoottil,C.; Sondej,T.; Hugen,C. M.; Flanigan,R. C.; Steinberg,G. D.ISRN urology 2013 ;2013( ):405064

An Analysis of Leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancerFlanigan,R. C.; Polcari,A. J.; Shore,N. D.; Price,T. H.; Sims,R. B.; Maher,J. C.; Whitmore,J. B.; Corman,J. M.The Journal of urology 2013 ;189(2):521-526

Legends in UrologyFlanigan,R. C.; Speh,A. J.; Speh,C. R.The Canadian journal of urology 2013 ;20(6):6998-7000

Renal Lymph Nodes for Tumor Staging: Appraisal of 871 Nephrectomies With Examination of Hilar FatMehta,V.; Mudaliar,K.; Ghai,R.; Quek,M. L.; Milner,J.; Flanigan,R. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2013 ; ( ):

Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6Mehta,V.; Rycyna,K.; Baesens,B. M.; Barkan,G. A.; Paner,G. P.; Flanigan,R. C.; Wojcik,E. M.; Venkataraman,G.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2012 ;5(6):496-502

Prognostic variables and nomograms for renal cell carcinomaFlanigan,R. C.; Polcari,A. J.; Hugen,C. M.International Journal of Urology 2011 ;18(1):20-31

Vanishing prostate cancer on radical prostatectomy (RP) in the PSA era: incidence and follow-up data from a cohort of 1,060 patients between 1998 and 2010Mehta,V.; Mehrotra,S.; Flanigan,R. C.; Wojcik,E. M.; Venkataraman,G.Virchows Archiv : an international journal of pathology 2011 ;459(1):115-116

Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer.Hugen,C. M.; Polcari,A. J.; Fitzgerald,M. P.; Dauw,C.; Flanigan,R. C.; Quek,M. L.Journal of surgical oncology 2010 ;102(4):334-337

Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.Hugen,C. M.; Polcari,A. J.; Quek,M. L.; Garza,R. P.; Fitzgerald,M. P.; Flanigan,R. C.World journal of urology 2010 ;28(6):741-744

The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function.Mulhall,J. P.; Parker,M.; Waters,B. W.; Flanigan,R. C.BJU international 2010 ;105(1):37-41

Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak.Tal,R.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.Journal of Sexual Medicine 2009 ;6(10):2813-2819

Penile rehabilitation following radical prostatectomy: predicting successMuller,A.; Parker,M.; Waters,B. W.; Flanigan,R. C.; Mulhall,J. P.The journal of sexual medicine 2009 ;6(10):2806-2812

Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy.Venkataraman,G.; Rycyna,K.; Rabanser,A.; Heinze,G.; Baesens,B. M.; Ananthanarayanan,V.; Paner,G. P.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.Journal of Urology 2009 ;181(1):88-93

Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.Flanigan,R. C.; Polcari,A.European urology 2009 ;55(4):990-991

The role of lymph node density in bladder cancer prognosticationQuek,M. L.; Flanigan,R. C.World journal of urology 2009 ;27(1):27-32

Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.Lara,P. N.,Jr; Tangen,C. M.; Conlon,S. J.; Flanigan,R. C.; Crawford,E. D.Journal of Urology 2009 ;181(2):512-516

Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology.Masoom,S.; Venkataraman,G.; Jensen,J.; Flanigan,R. C.; Wojcik,E. M.Cytopathology 2009 ;20(1):50-55

Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer.Polcari,A. J.; Hugen,C. M.; Sivarajan,G.; Woods,M. E.; Paner,G. P.; Flanigan,R. C.; Quek,M. L.Journal of Endourology 2009 ;23(8):1313-1317

The role of cytoreductive nephrectomy in the era of molecular targeted therapyPolcari,A. J.; Gorbonos,A.; Milner,J. E.; Flanigan,R. C.International Journal of Urology 2009 ;16(3):227-233

Maintenance of Certification: what is it and why is it happening.Flanigan,R. C.; Howards,S. S.AUA Update Series 2008 ;27( ):

Urine cytology for surveillance of the remnant urothelium after radical cystectomy and urinary diversionFok,C. S.; Liu,L.; Venkataraman,G.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.; Quek,M. L.Journal of Urology 2008 ;179(4 Supplement):249

Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas.Meyer,P. N.; Cao,Y.; Jacobson,K.; Krausz,T.; Flanigan,R. C.; Picken,M. M.Diagnostic Molecular Pathology 2008 ;17(3):141-144

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.Wood,C.; Srivastava,P.; Bukowski,R.; Lacombe,L.; Gorelov,A. I.; Gorelov,S.; Mulders,P.; Zielinski,H.; Hoos,A.; Teofilovici,F.; Isakov,L.; Flanigan,R. C.; Figlin,R.; Gupta,R.; Escudier,B.Lancet 2008 ;372(9633):145-154

Prostate specific antigen (PSA)-based screening.Suzuki,H.; Flanigan,R. C.; Okuyama,A.International Journal of Urology 2008 ;15(9):757-762

Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization.Picken,M. M.; Chyna,B.; Flanigan,R. C.; Lee,J. M.American Journal of Clinical Pathology 2008 ;129(3):377-382

Renal cell carcinoma in two patients with crossed fused ectopic kidneys.Davis,C. M.; Rao,M. V.; Flanigan,R. C.; Quek,M. L.Urologia internationalis 2008 ;81(3):370-372

The importance of histology and cytogenetics in decision making for renal cell carcinoma.Garcia,J. G.; Picken,M. M.; Flanigan,R. C.World journal of urology 2008 ;26(2):155-160

High incidence of aneuploidy in low grade urothelial carcinomasAlvarez,A.; Venkataraman,G.; Quek,M.; Flanigan,R.; Wojcik,E.International Journal of Urology 2008 ;15(3):279-279

Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer.Freeman,V. L.; Flanigan,R. C.; Meydani,M.Cancer Causes & Control 2007 ;18(2):211-218

Self-reported volume of radical prostatectomies among urologists in the USA.Denberg,T. D.; Flanigan,R. C.; Kim,F. J.; Hoffman,R. M.; Steiner,J. F.BJU international 2007 ;99(2):339-343

The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.Kositsawat,J.; Flanigan,R. C.; Meydani,M.; Choi,Y. K.; Freeman,V. L.Journal of Urology 2007 ;178(6):2391-2396

High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies.Paner,G. P.; Lindgren,V.; Jacobson,K.; Harrison,K.; Cao,Y.; Campbell,S. C.; Flanigan,R. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2007 ;131(1):81-85

Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.Nagda,S. N.; Mohideen,N.; Lo,S. S.; Khan,U.; Dillehay,G.; Wagner,R.; Campbell,S.; Flanigan,R. C.International journal of radiation oncology, biology, physics 2007 ;67(3):834-840

Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.Meyer,P. N.; Clark,J. I.; Flanigan,R. C.; Picken,M. M.American Journal of Clinical Pathology 2007 ;128(1):70-79

Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method.Kapur,U.; Antic,T.; Venkataraman,G.; Durazo-Arvizu,R. A.; Quek,M. M.; Flanigan,R. C.; Wojcik,E. M.Urology 2007 ;70(5):1028-1033

Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer.Venkataraman,G.; Heinze,G.; Holmes,E. W.; Ananthanarayanan,V.; Bostwick,D. G.; Paner,G. P.; Bradford-De La garza,C. M.; Brown,H. G.; Flanigan,R. C.; Wojcik,E. M.Prostate 2007 ;67(14):1524-1536

Renal tumors: the good, the bad, and the uglyFlanigan,R. C.International Journal of Urology 2007 ;14(7):575-580

Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney.Quek,M. L.; Basrawala,Z.; McClung,C.; Flanigan,R. C.Urology 2006 ;68(3):672.e21-672.e22

Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning.Venkataraman,G.; Ananthanarayanan,V.; Paner,G. P.; He,R.; Masoom,S.; Sinacore,J.; Flanigan,R. C.; Wojcik,E. M.Virchows Archiv 2006 ;449(3):302-307

Urothelial-cell carcinoma and solitary kidney: outcomes with renal-sparing management.Milner,J. E.; Voelzke,B. B.; Flanigan,R. C.; Sharma,S. K.; Perry,K. T.; Turk,T. M.Journal of Endourology 2006 ;20(10):800-807

The relationship between threat appraisal and social constraints in cancer survivors and their spouses.Herzer,M.; Zakowski,S. G.; Flanigan,R. C.; Johnson,P.Journal of Behavioral Medicine 2006 ;29(6):549-560

Utility of prostate biopsy morphometric sum optical density for identifying extraprostatic extension on subsequent prostatectomy.Bargaje,A.; Venkataraman,G.; Flanigan,R. C.; Wojcik,E. M.; Ananthanarayanan,V.Analytical & Quantitative Cytology & Histology 2006 ;28(6):343-345

Subspecialty certification in urology: a US perspective.Flanigan,R. C.Nature Clinical Practice Urology 2006 ;3(10):509

The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma.Denberg,T. D.; Kim,F. J.; Flanigan,R. C.; Fairclough,D.; Beaty,B. L.; Steiner,J. F.; Hoffman,R. M.Medical care 2006 ;44(12):1137-1141

Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells.Basrawala,Z.; Alimirah,F.; Xin,H.; Mohideen,N.; Campbell,S. C.; Flanigan,R. C.; Choubey,D.Oncogene 2006 ;25(19):2812-2817

Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma?.Flanigan,R. C.Nature Clinical Practice Urology 2005 ;2(12):588-589

Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System.Cao,Y.; Paner,G. P.; Perry,K. T.; Flanigan,R. C.; Campbell,S. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2005 ;129(4):487-491

Risk assessment for occult malignancy in the prostate before radical cystectomy.Kefer,J. C.; Voelzke,B. B.; Flanigan,R. C.; Wojcik,E. M.; Waters,W. B.; Campbell,S. C.Urology 2005 ;66(6):1251-1255

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109Van Veldhuizen,P. J.; Faulkner,J. R.; Lara,P. N.,Jr; Gumerlock,P. H.; Goodwin,J. W.; Dakhil,S. R.; Gross,H. M.; Flanigan,R. C.; Crawford,E. D.; Southwest Oncology GroupCANCER CHEMOTHERAPY AND PHARMACOLOGY 2005 ;56(1):39-45

The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function.Mulhall,J.; Land,S.; Parker,M.; Waters,W. B.; Flanigan,R. C.Journal of Sexual Medicine 2005 ;2(4):532-540

The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population.Malaeb,B. S.; Martin,D. J.; Littooy,F. N.; Lotan,Y.; Waters,W. B.; Flanigan,R. C.; Koeneman,K. S.BJU international 2005 ;95(7):977-981

Renal tumors in young adultsEggener,S. E.; Rubenstein,J. N.; Smith,N. D.; Nadler,R. B.; Kontak,J.; Flanigan,R. C.; Waters,W. B.; Picken,M.; Campbell,S. C.Journal of Urology 2004 ;171(1):106-110

Pathologic quiz case: renal mass in an otherwise healthy man. Epithelioid angiomyolipoma.Rubinas,T. C.; Flanigan,R. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2004 ;128(1):e19-20

Written emotional disclosure buffers the effects of social constraints on distress among cancer patients.Zakowski,S. G.; Ramati,A.; Morton,C.; Johnson,P.; Flanigan,R. C.Health Psychology 2004 ;23(6):555-563

Innovations and challenges in renal cancer: consensus statement from the first international conferenceAtkins,M. B.; Avigan,D. E.; Bukowski,R. M.; Childs,R. W.; Dutcher,J. P.; Eisen,T. G.; Figlin,R. A.; Finke,J. H.; Flanigan,R. C.; George,D. J.; Goldberg,S. N.; Gordon,M. S.; Iliopoulos,O.; Kaelin,W. G.,Jr; Linehan,W. M.; Lipton,A.; Motzer,R. J.; Novick,A. C.; Stadler,W. M.; Teh,B. T.; Yang,J. C.; King,L.Clinical Cancer Research 2004 ;10(18 Pt 2):6277S-81S

Cytologic features of recurrent lymphoma involving the urinary bladder.Quinn,A. M.; Flanigan,R. C.; Sienko,A.; Wojcik,E. M.Diagnostic cytopathology 2004 ;31(3):185-188

Renal tumor with overlapping distal nephron morphology and karyotype.Lindgren,V.; Paner,G. P.; Flanigan,R. C.; Clark,J. I.; Campbell,S. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2004 ;128(11):1274-1278

Cytogenetic analysis of a series of 13 renal oncocytomas.Lindgren,V.; Paner,G. P.; Omeroglu,A.; Campbell,S. C.; Waters,W. B.; Flanigan,R. C.; Picken,M. M.Journal of Urology 2004 ;171(2 Pt 1):602-604

The prevalence and nature of orgasmic dysfunction after radical prostatectomy.Barnas,J. L.; Pierpaoli,S.; Ladd,P.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.BJU international 2004 ;94(4):603-605

Debulking nephrectomy in metastatic renal cancerFlanigan,R. C.Clinical Cancer Research 2004 ;10(18 Pt 2):6335S-41S

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysisFlanigan,R. C.; Mickisch,G.; Sylvester,R.; Tangen,C.; Van Poppel,H.; Crawford,E. D.Journal of Urology 2004 ;171(3):1071-1076

Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.Freeman,V. L.; Meydani,M.; Hur,K.; Flanigan,R. C.Cancer 2004 ;101(12):2744-2754

Metastatic juxtaglomerular cell tumor in a 52-year-old man.Duan,X.; Bruneval,P.; Hammadeh,R.; Fresco,R.; Eble,J. N.; Clark,J. I.; Vigneswaran,W. T.; Flanigan,R. C.; Picken,M. M.American Journal of Surgical Pathology 2004 ;28(8):1098-1102

Nephrectomy in metastatic renal cell carcinomaCampbell,S. C.; Flanigan,R. C.; Clark,J. I.Current Treatment Options in Oncology 2003 ;4(5):363-372

Cytoreductive nephrectomy in metastatic renal cancerFlanigan,R. C.Current urology reports 2003 ;4(1):36-40

Heat Shock Proteins: Biology and Potential Clinical Application.Flanigan,R. C.Kidney Cancer 2003 ;1(1):19-25

Radical retropubic prostatectomy - what works for meFlanigan,R. C.Contemporary Urology 2003 ;15(5):13-17

Metastatic renal cell carcinomaFlanigan,R. C.; Campbell,S. C.; Clark,J. I.; Picken,M. M.Current Treatment Options in Oncology 2003 ;4(5):385-390

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.Unger,J. M.; LeBlanc,M.; Crowley,J. J.; Grossman,H. B.; Natale,R. B.; Wozniak,A. J.; Berenson,J. R.; List,A. F.; Peters,W. A.,3rd; Flanigan,R. C.; Macdonald,J. S.; Al-Sarraf,M.; Thompson,I. M.; Coltman,C. A.,JrJournal of Clinical Oncology 2003 ;21(23 Suppl):246s-252s

Social barriers to emotional expression and their relations to distress in male and female cancer patients.Zakowski,S. G.; Harris,C.; Krueger,N.; Laubmeier,K. K.; Garrett,S.; Flanigan,R. C.; Johnson,P.British Journal of Health Psychology 2003 ;8(Pt 3):271-286

Role of nephrectomy in metastatic kidney cancerYonover,P. M.; Sharma,S. K.; Flanigan,R. C.Cancer Treatment & Research 2003 ;116( ):119-135

Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function.Mulhall,J. P.; Slovick,R.; Hotaling,J.; Aviv,N.; Valenzuela,R.; Waters,W. B.; Flanigan,R. C.Journal of Urology 2002 ;167(3):1371-1375

Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study.Whitehead,R. P.; Lew,D.; Flanigan,R. C.; Weiss,G. R.; Roy,V.; Glode,M. L.; Dakhil,S. R.; Crawford,E. D.Journal of Immunotherapy 2002 ;25(4):352-358

Role of nephrectomy in metastatic renal cell carcinoma.Flanigan,R. C.; Yonover,P. M.; Campbell,S. C.AUA Update Series 2002 ;21(13):242-248

Effect of prostatic edema on CT-based postimplant dosimetry.Dogan,N.; Mohideen,N.; Glasgow,G. P.; Keys,K.; Flanigan,R. C.International journal of radiation oncology, biology, physics 2002 ;53(2):483-489

The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy.Gatenby,R. A.; Gawlinski,E. T.; Tangen,C. M.; Flanigan,R. C.; Crawford,E. D.Cancer research 2002 ;62(18):5218-5222

Survival advantage of Interleukin-2 over Interferon Immunotherapy when combine with cytoreductive nephrectomy based on SWOP 8949-matched populations.Pantuck,A. J.; Zisman,A.; Chao,D.; Dorey,F.; Flanigan,R. C.; DeKernion,J. B.; Figlin,R.; Belldegrun,A.Journal of Urology 2002 ;167(Suppl 1):166

Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice.Ellis,T. M.; Moser,M. T.; Le,P. T.; Flanigan,R. C.; Kwon,E. D.International immunology 2001 ;13(4):553-558

Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group studySchroder,L. E.; Lew,D.; Flanigan,R. C.; Eisenberger,M. A.; Seay,T. E.; Hammond,N.; Needles,B. M.; Crawford,E. D.Urologic oncology 2001 ;6(4):145-148

The role of radical nephrectomy in metastatic renal cell carcinomaFlanigan,R. C.; Yonover,P. M.Seminars in urologic oncology 2001 ;19(2):98-102

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.Flanigan,R. C.; Salmon,S. E.; Blumenstein,B. A.; Bearman,S. I.; Roy,V.; McGrath,P. C.; Caton,J. R.,Jr; Munshi,N.; Crawford,E. D.New England Journal of Medicine 2001 ;345(23):1655-1659

The role of resection for patients with renal carcinomaFlanigan,R. C.; Yonover,P. M.Current oncology reports 2001 ;3(5):424-432

Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?.Piper,N. Y.; Bishoff,J. T.; Magee,C.; Haffron,J. M.; Flanigan,R. C.; Mintiens,A.; Van Poppel,H. P.; Thompson,I. M.; Harmon,W. J.Urology 2001 ;58(6):849-852

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.Mercader,M.; Bodner,B. K.; Moser,M. T.; Kwon,P. S.; Park,E. S.; Manecke,R. G.; Ellis,T. M.; Wojcik,E. M.; Yang,D.; Flanigan,R. C.; Waters,W. B.; Kast,W. M.; Kwon,E. D.Proceedings of the National Academy of Sciences of the United States of America 2001 ;98(25):14565-14570

Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?.Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Durazo-Arvizu,R. A.; Liao,Y.; Flanigan,R. C.; Waters,W. B.American Journal of Clinical Nutrition 2001 ;73(4):815-820

Should radical nephrectomy be performed in the face of surgically incurable disease?Yonover,P. M.; Flanigan,R. C.Current opinion in urology 2000 ;10(5):429-434

Prostatic levels of fatty acids and the histopathology of localized prostate cancer.Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.Journal of Urology 2000 ;164(6):2168-2172

Renal cell carcinoma with metastasis to the thyroid glandPitale,S. U.; Sizemore,G. W.; Bakhos,R.; DeJong,S. A.; Flanigan,R. C.; Emanuele,N. V.Urologic oncology 2000 ;5(4):173-175

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.Catalona,W. J.; Partin,A. W.; Slawin,K. M.; Naughton,C. K.; Brawer,M. K.; Flanigan,R. C.; Richie,J. P.; Patel,A.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; deKernion,J. B.; Southwick,P. C.; Loveland,K. G.; Parson,R. E.; Gasior,G. H.Urology 2000 ;55(3):372-376

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.Catalona,W. J.; Southwick,P. C.; Slawin,K. M.; Partin,A. W.; Brawer,M. K.; Flanigan,R. C.; Patel,A.; Richie,J. P.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; Gasior,G. H.; Loveland,K. G.; Bray,K. R.Urology 2000 ;56(2):255-260

Primary localized amyloidosis of the ureter and bladder managed by ileal interposition.Hafron,J. M.; Flanigan,R. C.Techniques in urology 2000 ;6(1):50-52

Bacillus Calmette-Guerin. Is monthly maintenance an option for transitional cell carcinoma of the bladder?Flanigan,R. C.; DeLaurentis,D. A.; Waters,W. B.; Kunz,K.Urologic oncology 2000 ;6(1):16-19

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II studyElias,L.; Lew,D.; Figlin,R. A.; Flanigan,R. C.; Thompson,M. E.; Triozzi,P. L.; Belt,R. J.; Wood,D. P.,Jr; Rivkin,S. E.; David,E.Cancer 2000 ;89(3):597-603

Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases.Bakhos,R.; Shankey,T. V.; Flanigan,R. C.; Fisher,S.; Wojcik,E. M.Diagnostic cytopathology 2000 ;22(2):65-69

The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.Gao,X.; Mohideen,N.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.; Leman,C. R.Journal of Urology 2000 ;164(6):1982-1986

Medical School
  • Case Western Reserve University School of Medicine
  • University Hospitals of Cleveland/Case Western Reserve University, Urology